Prior to creating Panacea Venture, James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life science investment. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Before KPCB China, James was a managing partner at Vivo Ventures. James has made more than 15 investments in China since 2007.

Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he held various senior positions in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

James is Chairman of Board at Kindstar Global and JHL Biotech, and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, EntreMed, and XW Laboratory.

James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. He was born in Taipei, Taiwan.